文献速递神经肌肉病

FindMND生物标志物计划:运动神经元病/肌萎缩侧索硬化尸检组织与生物体液中的蛋白质变化

The FindMNDBiomarker Program: Protein Changes in Motor Neuron Disease/Amyotrophic Lateral Sclerosis Postmortem Tissue and Biofluids.
PubMed 文献 · Ann Neurol · 2025-06-20

该研究合并分析了25项人类ALS生物样本的蛋白质组学研究,旨在识别在ALS尸检组织、脑脊液或血液中持续改变的蛋白质。共鉴定出1,458种ALS中改变的蛋白质,并发现几丁质酶和凝溶胶蛋白在ALS生物体液中方向一致且失调。研究还构建了可访问的FindMND Biomarker数据库,便于用户查询感兴趣蛋白质在ALS中的失调频率及样本类型。

要点

  • 合并25项蛋白质组学研究,鉴定出1,458种ALS中改变的蛋白质。
  • 几丁质酶和凝溶胶蛋白在ALS生物体液中呈现一致的失调方向。
  • FindMND Biomarker数据库可查询蛋白质失调频率及样本类型。

核心结论

  • 合并分析揭示了ALS中线粒体、细胞质和RNA结合蛋白在初级及后期受累区域的持续失调。
  • 几丁质酶和凝溶胶蛋白在ALS生物体液中表现出显著一致的失调方向和程度。
  • FindMND Biomarker数据库有助于优先选择ALS相关蛋白进行进一步验证和研究。

研究设计与样本

  • 对25项人类ALS生物样本的蛋白质组学研究进行合并分析。
  • 样本类型包括ALS尸检组织、脑脊液或血液。
  • 分析覆盖ALS病理主要区域和外周生物体液。

主要发现

  • 共鉴定出1,458种在ALS中改变的蛋白质。
  • 在ALS病理初级和后期受累区域,线粒体、细胞质和RNA结合蛋白呈现持续失调。
  • 几丁质酶和凝溶胶蛋白在ALS生物体液中方向一致且失调显著。
  • 尸检组织与生物体液的比较强化了若干已知蛋白质变化,并突出了可能驱动疾病发病机制的新兴趣蛋白。

临床怎么用

  • 可利用FindMND Biomarker数据库查询感兴趣蛋白质在ALS中的失调频率及样本类型。
  • 根据蛋白质失调最一致的生物样本类型,判断其反映疾病发病机制还是全身性变化。
  • 按可重复性和样本类型筛选蛋白质,有助于优先选择ALS相关蛋白进行进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Biomarkers of disease pathogenesis are critically needed for amyotrophic lateral sclerosis (ALS) to facilitate diagnosis and patient stratification into appropriate therapeutic trials. Proteomic studies offer significant potential to advance this, but reproducibility across laboratories is a key component toward identifying protein changes that can be translated into clinical applications. METHODS: A combined analysis of 25 proteomic studies in human ALS biospecimens was performed to identify proteins consistently altered in ALS postmortem tissue, cerebrospinal fluid, or blood, as well as across primary regions of ALS pathology and peripheral biofluids. We consolidated these datasets into a user-friendly database "FindMND Biomarker," which is an accessible search tool that allows users to quickly determine how often, and in which biospecimen types, their proteins of interest are dysregulated in patients with ALS. RESULTS: Our combined analysis identified 1,458 altered proteins in ALS, and revealed consistent dysregulation in mitochondrial, cytoplasmic, and RNA binding proteins in primary and later affected regions of ALS pathology. Remarkable consistency in the direction and dysregulation of chitinases and gelsolin proteins were observed across ALS biofluids. Comparisons of postmortem tissue and biofluids reinforce several known protein changes, and highlighted novel proteins of interest that may drive disease pathogenesis. INTERPRETATION: The biospecimen type in which protein dysregulation is most consistently identified provides important insight into disease, and whether these represent potential measures of disease pathogenesis or systemic changes. By streamlining proteins by reproducibility and biospecimen type, FindMNDBiomarker is a useful resource that provides new mechanistic insights, and facilitates the prioritization of ALS-associated proteins for further validation and investigation. ANN NEUROL 2025;98:788-800.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Adler GL, Kiernan MC, Tan RH, et al. The FindMNDBiomarker Program: Protein Changes in Motor Neuron Disease/Amyotrophic Lateral Sclerosis Postmortem Tissue and Biofluids. Ann Neurol. 2025. PMID: 40539764. doi:10.1002/ana.27300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。